Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development
Rheumatology (Oxford). 2025;64:1131–1137. doi: 10.1093/rheumatology/keae257
Floris et al. conducted a monocentric cohort study to assess the impact of biologic treatment on the development of PsA in patients with PsO. Treatment with biologics significantly reduced the likelihood of PsA development, with lower prevalence observed across different biologic classes and patterns of joint involvement.
This study enrolled 1023 adult PsO patients who underwent rheumatological assessment, comparing those treated with biologics to those untreated. Multivariate analysis evaluated PsA development risk, stratified by biologic class (TNFi, IL-17i, IL-23i/IL-12/23i) and historical PsO management periods. Key clinical and safety outcomes were analysed throughout.
